位于中国南京的剑桥大学-南京科技创新中心是剑桥大学在英国以外设立的首个研究机构。该中心致力于展现与中国高校、产业界、政府及其他合作伙伴合作的力量,开展当今卓越的学术研究,以改善未来城市居民的生活。新中心于2019年9月破土动工,相关研究将于今年启动,其中包括由TVPLab开展的针对亚洲人群肥胖心脏代谢并发症的研究。

与欧洲或北美的标准相比,中国人口的肥胖程度并不算特别严重,但随着“西方饮食和生活方式”的迅速扩张,中国人口的体重无疑在不断增加。目前,中国46%的成年人超重或肥胖。然而,更令人担忧的是,亚洲人群在体重指数低于白种人的情况下,更容易出现超重和肥胖的心脏代谢并发症。据估计,中国有1.1亿人患有2型糖尿病, 50%的人口患有心血管疾病。这种高易感性背后的机制尚不清楚,因此研究这个问题非常重要,因为它可能对中国的公共健康产生重大影响。
我们在南京的研究项目将重点阐明肥胖与其相关心脏代谢并发症之间的关联机制,尤其关注人类群体中已发现的遗传因素。剑桥实验室提出了两个关键的概念范式:脂肪组织扩张模型和脂毒性概念。我们已经证明,肥胖的代谢并发症通常发生在脂肪组织扩张失败且脂质无法有效储存时。因此,无法储存的过量脂质会“溢出”到外周器官,脂质在外周器官中积聚,从而导致脂毒性。如果遗传因素限制了脂肪组织的扩张能力,则该过程可能在体重增加的早期阶段发生,导致肥胖的代谢并发症比预期更早出现。这项研究与全球肥胖流行病息息相关,但对中国的肥胖人群可能更具现实意义。南京对这些机制的研究将与剑桥的研究项目高度整合,并将受益于与我们实验室合作的国际专家网络。
目前,我们与南京大学的合作比以往任何时候都更加有效,这得益于他们对“4CPPE”倡议的大力支持——点击此处了解更多信息。如需了解更多关于这项研究以及中心的信息,请访问我们的网站、中心的推特页面,或观看对维达尔-普伊格教授的采访。

TVPLab in Cambridge University Nanjing Centre of Technology and Innovation
We are contribute to educate the lay public from China about obesity and associated complications, which are a major problem in China. To read whole interview with
Prof. Antonio Vidal-Puig click on the link bellow:
In English:
news details (cunjc.org.cn)
In Chinese:
越来越多人,都将面临这个挑战! (qq.com)
Professor Antonio Vidal-Puig, member of the Academic Committee of Enlian Research Institute, academician of the British Academy of Medical Sciences, and Cambridge University, came to Guangdong, Hong Kong and Macao Biotechnology to carry out academic exchanges!
Dongguan Regional Cell Preparation Center 2022-11-17 12:19 Posted on Guangdong
https://mp.weixin.qq.com/s/YWAirfclM1Vcc0YOAjT-xQ
On November 16, 2022 , Professor Antonio Vidal-Puig, a member of the Academic Committee of Enlian Stem Cell Biotechnology Research Institute , a member of the British Academy of Medical Sciences, and the University of Cambridge, visited Dongguan Guangdong-Hong Kong-Macau Stem Cell Biotechnology Co., Ltd. and Enlian Research Institute to conduct in-depth discussions. Academic exchange. Wu Pingping, chairman of Guangdong-Hong Kong-Macau Biotechnology, and Tan Fengming, general manager, warmly welcomed and accompanied the visit and discussion.
Professor Antonio Vidal-Puig received his Doctor of Medicine degree from Valencia University School of Medicine in Spain in 1986, and his Doctor of Philosophy degree from Granada University School of Medicine in 1992. He has engaged in research work at Harvard Medical School and Cambridge University, and is currently at Cambridge University . Professor of Molecular Nutrition and Metabolic Biology, mainly engaged in research on the molecular mechanism of obesity and insulin resistance, the molecular mechanism of diabetes and cardiometabolic abnormal complications, and related drug intervention strategies. Published more than 170 papers in multiple international authoritative journals such as Nature, Cell, etc. He serves as the editorial board member of many international authoritative journals such as Diabetes and Biochemical Journal.
Professor Antonio Vidal-Puig walked into the GMP laboratory of the Enlian Research Institute to learn more about the stem cell laboratory and its functional divisions, advanced equipment, experimental platforms, and cooperation progress . The system standards are fully affirmed, and some forward-looking opinions with practical value and significance are put forward. It is hoped that our company will truly break through scientific research bottlenecks and technical barriers by strengthening close cooperation with scientific research institutions , continuously carry out product research and development updates, and accelerate the transformation of research results. .
Subsequently, Prof. Antonio Vidal-Puig, general manager of Guangdong-Hong Kong-Macao Biotechnology Tan Fengming, Dean of Enlian Research Institute Dr. Zou Jiangying, and the academic committee team of the research institute conducted in-depth discussions on the future development of the research institute, stem cell basic and clinical research , etc. through video conferences . Academic discussions and exchanges provide technical guidance and inspiration to the academic committee team of the institute. I believe that the new ideas, new methods, and new insights brought about by the close exchanges between the two sides in the future will have important guiding and practical significance for the academic vision of our company and the team members of the research institute, and for the inspiration of academic research ideas.
We are deeply honored and benefited a lot from the visiting guidance of Professor Antonio Vidal-Puig. Stem cells are the frontier field of the biomedicine and health industry. It is believed that in the future, Guangdong, Hong Kong and Macao biotechnology will closely follow the pace of national scientific research development and international frontiers, actively build a "bridge" between scientific research and industry, continue to improve clinical research and transformation capabilities, and provide cells Provide strong support for the development of the field of treatment and drug research and development, empowering and adding value to the development of human health.
"I like the vitality of Nanjing!" Interview with Professor Antonio Vidal-Puig from Cambridge University
Cambridge University Nanjing Science and Technology Innovation Center
From a clinician to a university professor, from Spain to the United States to Cambridge, England, Professor Antonio Vidal-Puig has been committed to exploring the relationship between obesity, metabolic diseases and genes, so as to help obese people better cope with complications.
As the PI of the center's "Research on the Mechanism and Control Strategies of Obesity-Related Metabolic Complications", in the previous PI online interview , Antonio Vidal-Puig, Professor of Molecular Nutrition and Metabolism at the University of Cambridge, shared the research principles and application prospects of the project During his short-term exchange in China recently, he talked face-to-face with his rich research experience, global academic outlook, and good impression of Nanjing. Let us enter the world of Professor Vidal-Puig through the interview.
https://mp.weixin.qq.com/s/gxKM2_vigNPJELesoND6tQ




.png)

